John H Beigel1. 1. National Institute of Allergy and Infectious Diseases (NIAID), Rockville, Maryland, USA.
Abstract
PURPOSE OF REVIEW: This review summarizes past and ongoing efforts for using polyclonal and monoclonal antibodies for the treatment of influenza, and is focused on products that have entered clinical trials. RECENT FINDINGS: At least three polyclonal and eight monoclonal antibody products have been tested in clinical trials for the treatment of influenza. Considered across the two classes of therapeutics, these products appear to be safe and well tolerated. However, the efficacy results have been mixed and inconclusive. To date, no products have consistently shown superiority to currently available antivirals. SUMMARY: No products within these two classes have been licensed, and several products appear to have stopped further clinical development. There are several ongoing studies that are anticipated to be completed or reported in the next 1-2 years which will be critical for understanding the value of polyclonal and monoclonal antibodies in the treatment of influenza.
PURPOSE OF REVIEW: This review summarizes past and ongoing efforts for using polyclonal and monoclonal antibodies for the treatment of influenza, and is focused on products that have entered clinical trials. RECENT FINDINGS: At least three polyclonal and eight monoclonal antibody products have been tested in clinical trials for the treatment of influenza. Considered across the two classes of therapeutics, these products appear to be safe and well tolerated. However, the efficacy results have been mixed and inconclusive. To date, no products have consistently shown superiority to currently available antivirals. SUMMARY: No products within these two classes have been licensed, and several products appear to have stopped further clinical development. There are several ongoing studies that are anticipated to be completed or reported in the next 1-2 years which will be critical for understanding the value of polyclonal and monoclonal antibodies in the treatment of influenza.
Authors: John H Beigel; Evgenia Aga; Marie-Carmelle Elie-Turenne; Josalyn Cho; Pablo Tebas; Carol L Clark; Jordan P Metcalf; Caroline Ozment; Kanakatte Raviprakash; Joy Beeler; H Preston Holley; Stephanie Warner; Carla Chorley; H Clifford Lane; Michael D Hughes; Richard T Davey Journal: Lancet Respir Med Date: 2019-09-30 Impact factor: 30.700
Authors: Jeremy J Lim; Anna C Nilsson; Michael Silverman; Nimer Assy; Priya Kulkarni; Jacqueline M McBride; Rong Deng; Chloe Li; Xiaoying Yang; Allen Nguyen; Priscilla Horn; Mauricio Maia; Aide Castro; Melicent C Peck; Joshua Galanter; Tom Chu; Elizabeth M Newton; Jorge A Tavel Journal: Antimicrob Agents Chemother Date: 2020-06-23 Impact factor: 5.191
Authors: Sareh Zhand; Marie Saghaeian Jazi; Saeed Mohammadi; Roozbeh Tarighati Rasekhi; Ghassem Rostamian; Mohammad Reza Kalani; Aida Rostamian; Jacob George; Mark W Douglas Journal: Int J Mol Sci Date: 2020-08-03 Impact factor: 5.923